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Summary
The Toll-like receptor 3 (TLR3) and TLR4-signaling
pathway that involves the adaptor protein TRIF
activates type I interferon (IFN) and proinflammatory
cytokine expression. Little is known about how TRIF
pathway-dependent gene expression is regulated. SH2-
containing protein tyrosine phosphatase 2 (SHP-2) is
awidelyexpressedcytoplasmic tyrosinephosphatase.
Here we demonstrate that SHP-2 negatively regulated
TLR4- and TLR3-activated IFN-b production. SHP-2
inhibited TLR3-activated but not TLR2-, TLR7-, and
TLR9-activated proinflammatory cytokine IL-6 and
TNF-a production. SHP-2 inhibited poly(I:C)-induced
cytokine production by a phosphatase activity-inde-
pendent mechanism. C-terminal domain of SHP-2 di-
rectly bound TANK binding kinase (TBK1) by interact-
ing with the kinase domain of TBK1. SHP-2 deficiency
increasedTBK1-activated IFN-bandTNF-aexpression.
TBK1 knockdown inhibited poly(I:C)-induced IL-6 pro-
duction in SHP-2-deficient cells. SHP-2 also inhibited
poly(I:C)-induced activation of MAP kinase pathways.
These results demonstrate that SHP-2 specifically neg-
atively regulate TRIF-mediatedgene expression in TLR
signaling, partially through inhibiting TBK1-activated
signal transduction.
Introduction
Toll-like receptors (TLRs) are the main receptors by
which immune cells recognize microbial conserved
components such as lipopolysaccharide (LPS), dsRNA,
and bacterial DNA. The signal transduction mechanisms
of TLRs have been intensively investigated (Takeda
et al., 2003; Barton and Medzhitov, 2003). Most of the
members of TLR family, except TLR3, activate immune
*Correspondence: caoxt@public3.sta.net.cncells through the cascade that involves myeloid factor
88 (MyD88), IL-1 receptor-associated kinase 1 (IRAK1),
tumor necrosis factor receptor-associated factor 6
(TRAF6), and TGF-b-activated kinase 1 (TAK1) proteins
and downstream MAP kinases (MAPKs) and the tran-
scription factor NF-kB to induce proinflammatory cyto-
kine production (Takeda et al., 2003; Barton and Medz-
hitov, 2003). TRIF was initially identified as a critical
MyD88-independent adaptor protein in TLR3 and TLR4
signal transduction (Hoebe et al., 2003a; Yamamoto
et al., 2003). Upon TLR3 or TLR4 activation, TRIF asso-
ciates with TANK-binding kinase (TBK1) and activates
downstream interferon-regulating factor 3 (IRF3), medi-
ating TLR3- and TLR4-activated type I interferon pro-
duction (Oshiumi et al., 2003; Fitzgerald et al., 2003).
TRIF also activates MAPKs and NF-kB and contributes
to proinflammatory cytokine production in TLR3 and
TLR4 signaling (Hoebe et al., 2003a; Yamamoto et al.,
2003). Thus, the TRIF-TBK1 pathway is essential for
TLR3- and TLR4-activated inflammatory cytokine pro-
duction, type I interferon-dependent gene expression,
and antigen-presenting cell maturation (Hoebe et al.,
2003a, 2003b; Yamamoto et al., 2003). In addition, re-
cent studies suggested that the TRIF-TBK1 pathway is
also involved in tumor vascularization by mediating the
production of angiogenesis-modulating factors (Korherr
et al., 2006).
Although the full activation of macrophages is neces-
sary for elimination of invading pathogens, inappropri-
ate production of IFN-b and proinflammatory cytokines
might promote the development of immunopathological
conditions such as endotoxin shock and autoimmune
responses (Karaghiosoff et al., 2003; Liew et al., 2005).
More than ten negative regulators have been shown to
prevent macrophages from production of excessive
proinflammatory cytokines such as TNF-a, IL-1b, and
IL-6 by targeting MyD88-dependent pathway upon
TLR activation. However, little is known about how
TRIF pathway-activated production of type I IFN and
inflammatory cytokine is negatively regulated. Given
the important roles of TRIF-dependent pathway in a vari-
ety of physiological or pathological processes, it will be
important to investigate how TRIF-dependent pathway
is regulated in TLR signaling (Liew et al., 2005).
The Src homology 2 domain-containing protein tyro-
sine phosphatase 2 (SHP-2) is an evolutionarily con-
served protein tyrosine phosphatase, containing two
SH2 domains at the N terminus, a central catalytic do-
main, and a C-terminal tail (Matthews et al., 1992; Neel
et al., 2003). SHP-2 positively regulates the signaling
pathways of cytokines and growth factors, such as insu-
lin, EGF, PDGF, FGF, IL-1, and IL-6 (Kharitonenkov et al.,
1997; Bennett et al., 1994; Qu, 2000; You et al., 2001). In
contrast to the positive role in the mitogenic pathways,
SHP-2 negatively regulates the Janus kinase (JAK)-
signal transducers and activators of transcription (STAT)
signaling pathway initiated by IFN-aand IFN-g (You et al.,
1999). SHP-2 may also have an inhibitory role in acti-
vation of T and B lymphocytes (Lee et al., 1998;
Feng, 1999; Sedy et al., 2005). In addition, dominantly
Immunity
920Figure 1. SHP-2 Negatively Regulates TRIF-Dependent Type I Interferon Production in TLR4 and TLR3 Signal Transduction in Macrophages
(A) Mouse peritoneal macrophages were transfected with control small RNA (Ctrl) or SHP-2 siRNA. After 36 hr, SHP-2 expression in the cells was
detected by immunoblot. Similar results were obtained in three independent experiments.
(B) 1.5 3 105 mouse peritoneal macrophages were transfected with control small RNA (Ctrl) or SHP-2 siRNA (siRNA) and then treated with
100 ng/ml LPS for indicated time period. IFN-b in the supernatants was measured by ELISA. Data are shown as mean6 SE of three independent
experiments (**p < 0.01).
(C) Mouse peritoneal macrophages were treated as described in (B). mRNA expression of IFN-4a (IFN-a) and IFN-b were analyzed. Data are
shown as mean 6 SD (n = 3; **p < 0.01). Similar results were obtained in three independent experiments.
(D) Mouse peritoneal macrophages were treated as in (B), but stimulated with poly(I:C) for 12 hr or indicated time period. IFN-b production was
measured by ELISA. Data are shown as mean 6 SE of three independent experiments (**p < 0.01).
(E) Female C57BL/6J mice (4 weeks old) were intraperitoneally injected with thioglycolate to elicit peritoneal macrophages. After 3 days, intra-
peritoneal siRNA transfection was performed. After 48 hr, intraperitoneal cells were collected, and SHP-2 expression in the cells was detected by
immunoblot. Similar results were obtained in three independent experiments.
(F) Female C57BL/6J mice (4 weeks old) were treated as in (E), but after 48 hr, the mice were treated with PBS or 10 mg/ml poly(I:C) intraperitoneal
administration. 1 hr later, peritoneal lavage was collected and IFN-b production in the lavage was detected by ELISA. Data are shown as mean6
SD (n = 5; *p < 0.05). Similar results were obtained in three independent experiments.
(G) Ptpn11+/+ and Ptpn112/2MEF were stimulated with 10 mg/ml poly(I:C) for indicated time period, and IFN-b mRNA expression in the cells and
IFN-b production in the supernatants was measured. Data are shown as mean 6 SE of three independent experiments (**p < 0.01).
(H) HEK 293 cells were transfected with 100 ng TRIF expressing plasmid, 100 IFN-b luciferase reporter plasmid, 10 ng pTK-Renilla-luciferase,
together with 100 ng SHP-2 plasmid or empty control plasmid. After 24 hr of culture, luciferase activity was measured and shown as mean 6
SD (n = 3; **p < 0.01). Similar results were obtained in three independent experiments.activating mutations in human PTPN11, encoding mu-
tant SHP-2, is related with Noonan Syndrome (Tartaglia
et al., 2001). In the present study, we demonstrate that
SHP-2 inhibits TRIF-dependent type I interferon (IFN-
a/b) and proinflammatory cytokine production, identify-
ing SHP-2 as a negative regulator of TRIF-dependent
TLR4 and TLR3 signal transduction.
Results
SHP-2 Negatively Regulates TRIF-Dependent Type I
Interferon Production in TLR4 and TLR3 Signaling
To investigate whether SHP-2 plays a role in TRIF- and
TBK1-dependent pathway, we initially examined theeffects of SHP-2 expression on TLR3 and TLR4 agonists
poly(I:C)- and LPS-induced type I interferon production
in macrophages. Previous studies showed that synthe-
sized small-interfering RNA could markedly suppress
targeted gene expression in mouse primary peritoneal
cells both in vitro and in vivo (Okazawa et al., 2005; Na-
kamichi et al., 2005). Thus, synthesized interfering RNA
targeting mouse SHP-2, SHP-2 siRNA, was used to sup-
press endogenous SHP-2 expression. SHP-2 siRNA
transfection resulted in more than 70% decrease in
SHP-2 expression in mouse peritoneal macrophages
(Figure 1A). As shown in Figure 1B, SHP-2 knockdown
significantly increased LPS-induced IFN-b production
in mouse peritoneal macrophages. The effect of SHP-2
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analyzed by quantitative RT-PCR. SHP-2 siRNA treat-
ment significantly increased LPS-induced IFN-b mRNA
expression (Figure 1C), demonstrating that SHP-2 in-
hibits LPS-induced IFN-b expression at both mRNA and
protein levels in macrophages. Similarly, SHP-2 siRNA
treatment significantly increased LPS-induced IFN-4a
mRNA expression (Figure 1C). Pretreatment with cyclo-
heximide (CHX), an inhibitor of protein synthesis, could
not diminish SHP-2 knockdown-mediated increase in
LPS-induced IFN-b mRNA expression (see Figure S1 in
the Supplemental Data available online). The effect of
SHP-2 knockdown on poly(I:C)-induced IFN-b produc-
tion was detected both in in vitro culture system and
in vivo. As shown in Figure 1D, SHP-2 siRNA treatment
significantly increased poly(I:C)-induced IFN-b produc-
tion in cultured primary macrophages. Furthermore,
SHP-2 siRNA intraperitoneal transfection suppressed
SHP-2 expression in intraperitoneal cells (Figure 1E)
and significantly increased poly(I:C)-induced IFN-b pro-
duction in peritoneal lavage (Figure 1F). To confirm the
negative regulatory role of SHP-2 in TLR3-mediated
IFN-b production, the effects of SHP-2 deficiency on
poly(I:C)-induced IFN-b mRNA expression and IFN-b
production in mouse embryonic fibroblast (MEF) were
observed. As shown in Figure 1G, poly(I:C)-induced
IFN-b mRNA expression and IFN-b production were sig-
nificantly increased in SHP-2-deficient (Ptpn112/2) MEF
compared with that in Ptpn11+/+ MEF. Because type I
interferon production in TLR3 and TLR4 signaling is
TRIF dependent, these results indicated that SHP-2 is
a negative regulator of TRIF pathway both in vitro and
in vivo. Supporting this conclusion, SHP-2 overexpres-
sion inhibited TRIF-induced IFN-b luciferase reporter
gene expression in 293 cells (Figure 1H).
SHP-2 Inhibits TLR3- but Not TLR2-, TLR7-, or TLR9-
Mediated Proinflammatory Cytokine Production
TRIF activates both type I interferon and proinflamma-
tory cytokine expression in TLR signaling. Thus, we also
observed the effect of SHP-2 deficiency on TRIF-acti-
vated TNF-a reporter gene expression in MEF. As shown
in Figure 2A, SHP-2 deficiency significantly increased
TRIF-activated TNF-a reporter gene expression in MEF,
suggesting that SHP-2 also inhibited TRIF-mediated
proinflammatory cytokine production. To investigate
whether SHP-2 inhibited TRIF-dependent proinflamma-
tory cytokine production, the effects of SHP-2 knock-
down on TLR3-mediated IL-6 and TNF-aproduction was
detected. As shown in Figure 2B, SHP-2 siRNA treat-
ment significantly increased poly(I:C)-induced TNF-a
and IL-6 production in primary peritoneal macrophages.
Consistently, SHP-2 siRNA treatment significantly in-
creased poly(I:C)-induced TNF-a mRNA expression in
the cells (Figure 2C). To investigate whether SHP-2
specifically inhibited TRIF-dependent proinflammatory
cytokine production, primary peritoneal macrophages
were stimulated with LTA, R837, and CpG ODN, the
agonists of TLR2, TLR7, and TLR9, respectively. SHP-2
siRNA treatment did not increase LTA-, R837-, and CpG
ODN-induced TNF-a and IL-6 production in primary
peritoneal macrophages (Figure 2D). We also detected
poly(I:C)-, LTA-, and R837-induced IL-6 production in
Ptpn11+/+ and Ptpn112/2 MEF. SHP-2 deficiency signif-icantly increased poly(I:C)-induced IL-6 mRNA expres-
sion (Figure 2E) and IL-6 production (Figure 2F) in MEF.
In contrast, SHP-2 deficiency did not increase LTA- and
R837-induced IL-6 production in MEF (Figure 2F). These
results provide further evidence that SHP-2 negatively
regulates TRIF-dependent signal transduction.
SHP-2 Negatively Regulates TRIF-Dependent
Activation of IRF3 and MAPK Pathways
IRF3 is the key transcription factor that is activated in
TRIF-dependent pathway and mediates the expression
of type I interferon in TLR3 and TLR4 signal transduc-
tion. We next observed the effect of SHP-2 overexpres-
sion on LPS-induced IFR3 activation by detecting IRF3
luciferase reporter gene expression. RAW264.7 cells
were transfected with pcDNA-SHP-2W plasmid encod-
ing wild-type SHP-2, or pcDNA empty control plasmid,
together with Gal4-IRF3-expressing plasmid plus Gal4
luciferase reporter plasmid. As shown in Figure 3A,
LPS-induced IRF3 activation was significantly inhibited
by SHP-2 overexpression in a dose-dependent manner.
To confirm the regulatory role of SHP-2 in TLR-activated
IRF3 activation, Ptpn11+/+ and Ptpn112/2 MEF were
transfected with Gal4-IRF3-expressing plasmid plus
Gal4 luciferase reporter plasmid, and then stimulated
with poly(I:C). SHP-2 deficiency significantly enhanced
both baseline and poly(I:C)-induced IRF3 activation
(Figure 3B). Consistently, SHP-2 deficiency significantly
enhanced LPS- and poly(I:C)-induced IFN-b luciferase
reporter gene expression (Figure 3C). These results
demonstrated that endogenous SHP-2 negatively regu-
lates IRF3 activation in TLR3 and TLR4 signaling. STAT1
activation enhances TLR4-mediated IFN-b production in
macrophages. However, SHP-2 siRNA inhibited LPS-
induced phosphorylation of STAT1 (Figure S2).
TRIF-dependent activation of MAPK pathways are
required for cytokine production in TLR3 signaling, and
therefore we investigated whether the activation of MAPK
pathways in TLR3 signaling was affected by SHP-2 ex-
pression. SHP-2 deficiency enhanced poly(I:C)-induced
ERK1 and ERK2, JNK1 and JNK2, and p38 MAPK activa-
tion in MEF, suggesting that SHP-2 negatively regulates
TRIF-dependent activation of MAPK pathways (Figure 3D).
Interestingly, SHP-2 deficiency also enhanced poly(I:C)-
induced IRAK1 phosphorylation (Figure S3).
SHP-2 Inhibits TBK1-Activated Gene Expression
TBK1 functions downstream of TRIF and is essential for
TRIF-induced IRF3 activation and IFN-a/b expression
(Fitzgerald et al., 2003). To investigate whether SHP-2 in-
hibited TBK1-activated signal transduction, Ptpn11+/+
and Ptpn112/2 MEF were transfected with TBK1-
expressing construct plus IFN-b reporter plasmid. As
anticipated, TBK1-activated IFN-b reporter gene ex-
pression was significantly increased in Ptpn112/2 MEF
compared with that in Ptpn11+/+ cells (Figure 4A).
To investigate whether TBK1 was involved in the
increase of poly(I:C)-induced proinflammatory cytokine
production in SHP-2-deficient MEF, the effect of SHP-
2 deficiency on TBK1-activated TNF-a reporter gene
expression in MEF was also investigated. SHP-2 defi-
ciency significantly increased TBK1-activated TNF-a re-
porter gene expression in MEF (Figure 4A). Furthermore,
TBK1 expression in MEF was suppressed with small
Immunity
922Figure 2. SHP-2 Negatively Regulates TRIF-Dependent Proinflammatory Cytokine Production
(A) Ptpn11+/+ and Ptpn112/2 MEF were transfected with 40 ng TNF-a luciferase reporter plasmid and 10 ng pTK-Renilla-luciferase, together
with 100 ng TRIF-expressing plasmid. Total amounts of plasmid DNA were equalized with pcDNA empty control vector. After 24 hr of culture,
luciferase activity was measured and normalized by Renilla luciferase activity. Data are shown as mean 6 SD (n = 3) of one typical experiment
(**p < 0.01). Similar results were obtained in three independent experiments.
(B) Mouse peritoneal macrophages were transfected with control small RNA (Ctrl) or SHP-2 siRNA (siRNA). After 36 hr, the cells were stimulated
with 10 mg/ml poly(I:C) for indicated time period. Concentrations of IL-6 and TNF-a in the supernatants were measured by ELISA. Data are shown
as mean 6 SE of three independent experiments (**p < 0.01).
(C) Mouse peritoneal macrophages were treated as described in (B), TNF-a mRNA expression in the cells was measured by real-time RT-PCR.
Data are shown as mean 6 SE of three independent experiments (**p < 0.01).
(D) Mouse peritoneal macrophages were transfected with control small RNA (Ctrl) or SHP-2 siRNA (siRNA). After 36 hr, the cells were stimulated
with 10 mg/ml LTA, 10 mg/ml R837, or 1 mM CpG ODN for 12 hr. Concentrations of IL-6 and TNF-a in the supernatants were measured by ELISA.
Data are shown as mean 6 SE of three independent experiments (**p < 0.01).
(E) Ptpn11+/+ and Ptpn112/2 MEF were stimulated with 10 mg/ml poly(I:C) for indicated time period, IL-6 mRNA expression in the cells was
assayed by real-time RT-PCR. Data are shown as mean 6 SE of three independent experiments (**p < 0.01).
(F) Ptpn11+/+ and Ptpn112/2 MEF were stimulated with 10 mg/ml poly(I:C), 10 mg/ml LTA, or 10 mg/ml R837 for 10 hr, IL-6 production was
measured by ELISA. Data are shown as mean 6 SE of three independent experiments (**p < 0.01).interfering RNA specific to TBK1 (Figure 4B). Although
TBK1 knockdown did not affect IL-6 production in
Ptpn11+/+ MEF, it significantly inhibited poly(I:C)-
induced IL-6 production in Ptpn112/2 MEF (Figure 4C).
These results suggested that TBK1-mediated signal
transduction is involved in poly(I:C)-induced proinflam-
matory cytokine production in Ptpn112/2 MEF.
SHP-2 Inhibits TRIF-Dependent Cytokine
Production in Tyrosine Phosphatase
Activity-Independent Manner
It has been well established that mutation of amino acid
463 from Cys to Ser disrupted the tyrosine phosphatase
activity of SHP-2 (Yin et al., 1997). To investigate whetherSHP-2 inhibited TRIF-activated cytokine production
through its phosphatase activity, RAW264.7 macro-
phages stably transfected with SHP-2W or SHP-2CS
plasmids were stimulated with poly(I:C), and then TNF-a,
IL-6, and IFN-b production was detected. Both SHP-2W
and SHP-2CS inhibited poly(I:C)-induced TNF-a, IL-6,
and IFN-b production (Figure 5), suggesting that SHP-2
inhibits poly(I:C)-induced TNF-a, IL-6, and IFN-b produc-
tion in a phosphatase activity-independent manner.
SHP-2 Interacts with TBK1 and Inhibits
TBK1-Activated IFN-b Expression
To understand the mechanisms by which SHP-2 nega-
tively regulates TBK1-activated gene expression, we
SHP-2 Inhibits TRIF and TBK1 Signals
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with TBK1 in TLR signal transduction. After poly(I:C)
treatment, RAW264.7 macrophages were lysed and
Figure 3. SHP-2 Negatively Regulates TRIF-Dependent Activation
of IRF3 and MAPK Pathways
(A) RAW264.7 macrophages were transfected with 100 ng IRF3 lucif-
erase reporter plasmids (80 ng Gal4 luciferase reporter plasmid, 20 ng
Gal4-IRF3 expressing plasmid), 100 ng pTK-Renilla-luciferase, and
indicated dose of SHP-2. Total amounts of plasmid DNA were equal-
ized with pcDNA empty control vector. After 24 hr of culture, the cells
were stimulated with 100 ng/ml LPS for 6 hr. Luciferase activity was
measured and normalized by Renilla luciferase activity. Data are
shown as mean 6 SD (n = 3) of one typical experiment (**p < 0.01).
Similar results were obtained in three independent experiments.
(B) Ptpn11+/+ and Ptpn112/2 MEF were transfected with 100 ng IRF3
luciferase reporter plasmids (80 ng Gal4 luciferase reporter plasmid,
20 ng Gal4-IRF3 expressing plasmid), 10 ng pTK-Renilla-luciferase.
After 24 hr of culture, the cells were stimulated with 10 mg/ml poly(I:C)
for 6 hr. Luciferase activity was measured and normalized by Renilla
luciferase activity. Data are shown as mean6SD (n = 3) of one typical
experiment (**p < 0.01). Similar results were obtained in three inde-
pendent experiments.
(C) Ptpn11+/+ and Ptpn112/2 MEF were transfected with 40 ng IFN-
b luciferase reporter construct and 10 ng pTK-Renilla-luciferase plas-
mid. After 24 hr of culture, the cells were stimulated with 10 mg/ml LPS
or 10 mg/ml poly(I:C) for 4 hr. Luciferase activity was measured and
normalized by Renilla luciferase activity. Data are shown as mean6
SD (n = 6) of one typical experiment (**p < 0.01). Similar results were
obtained in three independent experiments.
(D)Ptpn11+/+ andPtpn112/2MEF were treated with 10mg/ml poly(I:C)
for the indicated time. Phospho-ERK, phospho-38, phospho-JNK,
and total ERK, p38, and JNK were detected by immunoblot. Similar
results were obtained in three independent experiments.SHP-2 was precipitated with specific SHP-2 antibody,
and TBK1 was coprecipitated with SHP-2 after poly(I:C)
treatment (Figure 6A). Reverse immunoprecipitation
experiments were also carried out with TBK1-specific
antibody, and SHP-2 was coprecipitated (Figure 6A),
suggesting that endogenous SHP-2 was recruited to
TBK1 upon TLR3 activation.
TBK1 was considered an essential intermediator
downstream of TRIF in TLR3 signaling. Interestingly,
mutation of K38A in the N-terminal domain of TBK1
blocked the binding of TBK1 to TRIF, suggesting that
the kinase activity of TBK1 was required for the associ-
ation between TBK1 and TRIF (Sato et al., 2003). We
constructed mutant TBK1 K38A plasmid and coex-
pressed TBK1 K38A and SHP-2 in 293 cells. The K39A
mutation did not significantly affect the association be-
tween TBK1 and SHP-2 (Figure S4), suggesting that
the association between TBK1 and SHP-2 was not de-
pendent on the formation of TRIF-TBK1 complex.
To determine whether SHP-2 could directly bind
TBK1, purified active recombinant TBK1 was incubated
with E. coli-expressed GST-tagged SHP-2 amino acids
230–545, and then pull-down assay was performed with
glutathione-agarose. Blotting with TBK1-specific anti-
body revealed that TBK1 could be pulled down with
GST-tagged SHP-2(230-545) (Figure 6B). More impor-
tantly, incubation with recombinant SHP-2(230-545) in-
hibited TBK1-mediated phosphorylation of myelin basic
protein (MBP) (Figure 6C), demonstrating that SHP-2
could directly bind TBK1 and inhibit phosphorylation
of substrate by TBK1. We constructed the truncated
SHP-2 mutants (Figure S5) and investigated whether
C-terminal domain of SHP-2 interacted with TBK1 in
HEK293 cells. As shown in Figure 6D, C-terminal domain
(SHP-2C273) rather than N-terminal SH2 domain of
SHP-2 (SHP-2N233) was associated with TBK1. Tyro-
sine residues 546 and 584 in C-terminal domain of
SHP-2 were reported to be required for the interaction
between SHP-2 and several molecules (Vogel and
Ullrich, 1996). However, truncated SHP-2C273-538
could still coprecipitate TBK1 (Figure S6), suggesting
that these tyrosine residues were not required for the in-
teraction between SHP-2 and TBK1. Consistently, SHP-
2C273, SHP-2C273-538, and mutant SHP-2C273CS
significantly inhibited TBK1-activated IFN-b expression
(Figure 6E).
To determine how SHP-2 bound to TBK1, truncated
TBK1 mutants were constructed (Figure S7) and
coexpressed with SHP-2 in 293 cells. As shown in
Figure 6F, SHP-2 could be coprecipitated with N-termi-
nal domain of TBK1 (TBK1N242). In contrast, C-terminal
domain of TBK1 (TBK1C243) failed to precipitate SHP-2.
Similarly, truncated C-terminal domain TBK1C243-392
could not precipitate SHP-2 (Figure S8). These results
demonstrated that the binding between SHP-2 with
TBK1N242 domain was specific, suggesting that SHP-
2 could negatively regulate TBK1-mediated signal trans-
duction by binding to kinase domain of TBK1.
Discussion
In the present study, we demonstrate that SHP-2 nega-
tively regulates TLR4- and TLR3-mediated IFN-4a/b
expression in macrophages. We used SHP-2 siRNA to
Immunity
924Figure 4. SHP-2 Inhibits TBK1-Activated Gene Expression
(A) Ptpn11+/+ and Ptpn112/2 MEF were transfected with 40 ng IFN-b or TNF-a luciferase reporter plasmid and 10 ng pTK-Renilla-luciferase,
together with 100 ng TBK1-expressing plasmid. Total amounts of plasmid DNA were equalized with empty control vector. After 24 hr of culture,
luciferase activity was measured and normalized by Renilla luciferase activity. Data are shown as mean 6 SD (n = 6) of one typical experiment
(**p < 0.01). Similar results were obtained in three independent experiments.
(B) MEF were transfected with control small RNA (Ctrl) or TBK1-specific siRNA (TBK1 iRNA1 or TBK1 iRNA2). After 36 hr, TBK1 and b-actin
expression in the cells was detected by immunoblot. Similar results were obtained in three independent experiments.
(C) Ptpn11+/+ and Ptpn112/2 MEF were transfected with control small RNA (Ctrl) or TBK1-specific siRNA (TBK1 iRNA1 or TBK1 iRNA2). After
36 hr, the cells were stimulated with poly(I:C) for 6 hr. Concentration of IL-6 in the supernatants was measured by ELISA. Data are shown as
mean 6 SE of three independent experiments (**p < 0.01).suppress endogenous SHP-2 expression in primary
mouse peritonealmacrophages. Correlating with the sup-
pression of endogenous SHP-2 expression, LPS- and
poly(I:C)-induced IFN-4a/b expression was increased.
The negative regulatory role of SHP-2 in poly(I:C)-
induced type I interferon was confirmed in Ptpn112/2
MEF.
LPS-induced IFN-a/b expression is TRIF dependent.
However, SHP-2 functions in a variety of cytokine signal
transduction pathways, some of which might affect
LPS-induced IFN-a/b expression. In particular, the acti-
vation of STAT1 was reported to play a role in LPS-
induced IFN-b production (Toshchakov et al., 2002).
Thus, the effect of SHP-2 expression on LPS-induced
activation of STAT1 was investigated. SHP-2 siRNA in-hibited LPS-induced phosphorylation of STAT1, ruling
out the possibility that SHP-2 siRNA increases LPS-
induced IFN-b production through STAT1 pathway. In
addition, we also used CHX to inhibit LPS-induced
protein synthesis. In the presence of CHX, SHP-2 knock-
down could still significantly increase LPS-induced
IFN-b mRNA expression, demonstrating that the regula-
tion of LPS-induced IFN-b mRNA expression by SHP2 is
independent on synthesis of novel protein and providing
additional evidence that SHP-2 directly regulates TLR4
signaling.
TBK1 is essential for TRIF-induced IRF3 activation
and IFN-a/b expression. TBK1 siRNA or kinase-inactive
TBK1 blocked TRIF-induced IRF3 activation (Fitzgerald
et al., 2003). Immunoprecipitation experiments revealedFigure 5. SHP-2 Inhibits TLR3-Activated Cytokine Production in Phosphatase Activity-Independent Manner
RAW264.7 macrophages stably transfected with SHP-2W, SHP-2CS plasmid, or empty control vector were stimulated with poly(I:C), then TNF-a,
IL-6, and IFN-b in the supernatants were measured by ELISA. Data are shown as mean 6 SE of three independent experiments (**p < 0.01).
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TBK1. IFN-b and TNF-a reporter gene expression assay
demonstrated that SHP-2 deficiency significantly in-
creased TRIF- and TBK1-activated gene expression.
These results suggested that SHP-2 inhibits poly(I:C)-
induced proinflammatory cytokine and type I IFN
expression at least partially through TRIF- and TBK1-
dependent pathway.
SHP-2 directly bound to TBK1 and inhibited TBK1-
mediated phosphorylation of MBP. SHP-2 functions as
a tyrosine phosphatase. However, tyrosine phosphory-
lation of recombinant active TBK1 could not be detected
with phospho-tyrosine antibody (data not shown). In ad-
dition, mutation of C463S, which disrupted the tyrosine
phosphatase activity of SHP-2, did not reverse the inhi-
bition of poly(I:C)-induced IFN-b production and TBK1-
activated IFN-b reporter gene expression by SHP-2.
Thus, it appeared that SHP-2 inhibited the activity of
TBK1 through a tyrosine phosphatase activity-indepen-
dent mechanism. Instead, SHP-2 might prevent TBK1-
mediated downstream substrate phosphorylation by
binding to kinase domain of TBK1.
TBK1 phosphorylates IKK-b and has been implicated
in NF-kB activation. However, poly(I:C)- and LPS-
induced NF-kB activation and IL-6 production are nor-
mal in TBK1-deficient cells (Hemmi et al., 2004). These
results suggested that TBK1 might not participate in
TLR-activated NF-kB activity and proinflammatory cyto-
kine production. Alternatively, TBK1 might be redundant
for TLR-activated NF-kB activation. Another explanation
for the inconsistency might be that some negative regu-
lators of TBK1 exist and limit the role of TBK1 in proin-
flammatory cytokine production in TLR signaling. This
was consistent with our observation that TBK1 induced
significant TNF-a reporter gene expression in Ptpn112/2
cells but only marginal TNF-a reporter gene expression
in Ptpn11+/+ MEF, and was further supported by the
results that TBK1 knockdown did not affect poly(I:C)-
induced IL-6 production in Ptpn11+/+ MEF but signifi-
cantly decreased poly(I:C)-induced IL-6 production in
Ptpn112/2 cells.
Presently, there is no report that TBK1 could activate
MAPK pathways. Thus, there might be some molecules
that contributed to the increased poly(I:C)-induced
proinflammatory cytokine production in TBK1-indepen-
dent manner in SHP-2-deficient cells. IRAK1 plays an
important role in LPS-induced ERK1, ERK2, p38, JNK1,
and JNK2 activation. SHP-2 deficiency significantly
enhanced poly(I:C)-induced phosphorylation of IRAK1.
However, it was reported that MAPKs were activated
through IRAK1-independent pathway in poly(I:C)-in-
duced TLR3 signal transduction (Jiang et al., 2003). Our
future study will focus on how SHP-2 inhibits poly(I:C)-
induced phosphorylation of IRAK1 and whether IRAK1
plays a role in poly(I:C)-induced MAPKs activation and
downstream proinflammatory cytokine production in
SHP-2-deficient cells.
Active control of the magnitude of immune response
to microbial pathogens and endogenous TLR ligands
by restricting TLR signaling is essential for protecting
the host from the injury induced by excessive activation.
Recent studies have identified multiple negative regula-
tors functioning at different levels of TLR4 signaling,
most of which target MyD88-IRAK-TRAF6 signal cas-cade (Liew et al., 2005; Kobayashi et al., 2002; Wald
et al., 2003; Brint et al., 2004; Boone et al., 2004). A pre-
vious study showed that A20 also negatively regulates
IRF3 activation in TLR3 signal transduction (Saitoh
et al., 2005). However, it remains unknown whether
these molecules also affect TRIF-dependent TLR4 sig-
naling. To our knowledge, our results provide the first
evidence that TRIF-dependent TLR4 and TLR3 signal
transduction might be strictly controlled by SHP-2.
In conclusion, by identifying SHP-2 as a critical nega-
tive regulator of TRIF-dependent pathway, the present
study provides insight into the mechanism of TRIF-de-
pendent signal transduction. SHP-2 specifically inhibits
MyD88-independent proinflammatory cytokine and type
I interferon production in TLR3 and TLR4 signal trans-
duction. Upon TLR3 activation, SHP-2 is recruited and
directly binds to kinase domain of TBK1, resulting in
the suppression of TBK1-mediated substrate phosphor-
ylation and cytokine production. SHP-2 also inhibits
TLR3-activated IRAK1 and MAPK pathways. These
results demonstrate that SHP-2 negatively regulates
TRIF-dependent cytokine production at least partially
through inhibiting TBK1-mediated signal transduction.
Experimental Procedures
Mice and Reagents
C57BL/6J mice were obtained from Joint Ventures Sipper BK Exper-
imental Animal (Shanghai, China). All animal experiments were un-
dertaken in accordance with the National Institute of Health Guide
for the Care and Use of Laboratory Animals, with the approval of
the Scientific Investigation Board of Second Military Medical Univer-
sity, Shanghai. Poly(I:C) and LPS (0111:B4) was purchased from
Sigma (St. Louis, MO), and LPS was repurified as described (Hirsch-
feld et al., 2000). Antibodies specific to SHP-2, Myc-tag, TBK1,
IRAK1, p38, ERK, JNK, and horseradish peroxidase-coupled sec-
ondary antibodies were obtained from Santa Cruz (Santa Cruz,
CA). Phospho-p38, phospho-ERK, and phospho-JNK antibodies
were obtained from Cell Signaling Technology (Beverly, MA). Puri-
fied recombinant active His6-tagged TBK1 protein, expressed by
baculovirus in Sf21 cells, and GST-tagged SHP-2 (amino acid
330–545) protein, expressed in E. coli, were purchased from Upstate
Biotechnology (Lake Placid, NY).
Cell Culture
Female C57BL/6J mice (5–6 weeks old) were used for the prepara-
tion of primary mouse macrophages, and thioglycolate-elicited
mouse peritoneal macrophages were prepared as described (Kara-
ghiosoff et al., 2003). The cells were cultured in endotoxin-free
DMEM with 10% FCS (PAA Laboratories, Pasching, Austria). After
1 hr, nonadherent cells were removed. On the next day, the cells
were transfected with Geneporter 2 Transfection Reagent (GTS,
San Diego, CA) according to manufacturer’s instructions. Wild-
type (Ptpn11+/+) and SHP-2-deficient (Ptpn112/2) mouse embryonic
fibroblast (MEF) were established and cultured as described previ-
ously (You et al., 2001). Mouse macrophage cell line RAW 264.7
and human HEK 293 cells were obtained from the American Type
Culture Collection (Manassas, VA) and cultured as described (An
et al., 2005).
Plasmid Constructs and Transfection
Plasmids containing wild-type SHP-2 (pcDNA3-SHP-2W) and tyro-
sine phosphatase inactive mutant SHP-2 (pcDNA3-SHP-2CS) were
constructed as described previously (Yin et al., 1997). Mouse cDNAs
encoding TRIF and TBK1 were amplified from mRNA of RAW264.7
cells by RT-PCR, cloned into pcDNA3.1 expression vector, and
sequenced (Invitrogen, Carlsbad, CA). Myc-tagged SHP-2 and
TBK1 constructs were generated by PCR. IRF3 reporter plasmids
were kind gifts from Dr. T. Fujita (Tokyo Metropolitan Institute of
Medical Science) (Shinobu et al., 2002). Mouse DNAs for IFN-b and
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(A) RAW264.7 cells were treated with 10 mg/ml poly(I:C) for indicated time period. Equal amount of cell lysates were immunoprecipitated (IP) with
SHP-2 or TBK1-specific antibody. Precipitated proteins were blotted (IB) with SHP-2 and TBK1-specific antibody. Protein in whole-cell lysate (W)
was used as positive control. Similar results were obtained in three independent experiments.
(B) Recombinant active TBK1 was incubated with GST-tagged recombinant SHP-2(230-545) or GST control recombinant protein. GST pull-down
assay was performed with glutathione-agarose and blotted with TBK1-specific antibody. Similar results were obtained in three independent
experiments.
(C) MBP was incubated with recombinant active TBK1, and MBP phosphorylation was detected as described in Experimental Procedures. Data
are shown as mean 6 SD (n = 3) of one typical experiment (**p < 0.01). Similar results were obtained in three independent experiments.
(D) TBK1 construct together with HA-tagged SHP-2, SHP-2N233, or SHP-2C273 plasmids were transfected into HEK293 cells. After 24 hr, SHP-2
truncates were immunoprecipitated (IP) with HA-specific antibody. Precipitated proteins were detected by immunoblot (IB). Similar results were
obtained in three independent experiments.
(E) HEK293 cells were transfected with 40 ng IFN-b luciferase reporter plasmid, 10 ng pTK-Renilla-luciferase, 100 ng TBK1 expressing plasmid,
together with indicated amount of SHP-2-expressing plasmid. Total amounts of plasmid DNA were equalized with empty control vector. After
24 hr of culture, luciferase activity was measured and normalized byRenilla luciferase activity. Data are shown as mean6SD (n = 6) of one typical
experiment (**p < 0.01). Similar results were obtained in three independent experiments.
SHP-2 Inhibits TRIF and TBK1 Signals
927TNF-a promoter were amplified from RAW264.7 cells by PCR and
cloned in pGL3 plasmid (Promega) to construct IFN-b and TNF-a lu-
ciferase reporter plasmids. The primers used are TNF-a-F 50ccatctg
tgaaacccaataaacctc30, TNF-a-R 50gggagatgtggcgccttgg30, IFN-b-F
50agcttgaataaaatgctagctagaagctgttagaa30, and IFN-b-B 50caagatg
aggcaaagcttcaaaggctgcagtgagaat30. All constructs were confirmed
by DNA sequencing. For stable transfection, RAW264.7 macro-
phages were seeded into dishes and transfected with Lipofectamine
2000 (Invitrogen) according to manufacturer’s instructions. The
cells were selected with 300 ng/ml G418 and pooled for further
experiments.
RNA Interfering
SHP-2 siRNA, small interfering RNA targeting SHP-2, was described
previously (Kontaridis et al., 2004). TBK1 siRNA, small interfering
RNA targeting TBK1, were ctgtgaaagtgtatgagaa (TBK1 iRNA1) and
cacatgacggcgcataaga (TBK1 iRNA2). The control siRNA sequence
was 50aatcagtcacgttaatggtcg30. For 1 3 106 cells, 0.4 nmol SHP-2
siRNA was mixed with 15 ml Geneporter 2 Transfection Reagent
and transfected into the cells. After 6 hr, the supernatant was re-
moved and fresh medium was added. The cells were cultured for
another 36 hr before further experiments.
In Vivo siRNA Transfection
Female C57BL/6J mice (4 weeks old) were intraperitoneally injected
with thioglycolate to elicit peritoneal macrophages. After 3 days,
6 nmol siRNA was incubated with Geneporter 2 Transfection
Reagent according to manufacturer’s instruction and then intraper-
itoneally injected. After 48 hr, the mice were treated with intraperito-
neal administration of TLR agonist.
Detection of IFN-b, TNF-a, and IL-6 Production
2 3 105 cells were seeded into 24-well plates and incubated over-
night. The cells were stimulated with 100 ng/ml LPS or 10 mg/ml
poly(I:C) for indicated time periods. The concentrations of IFN-b,
TNF-a, and IL-6 in culture supernatants were measured by ELISA
Kits (R&D Systems, Minneapolis, MN).
RNA Quantification
Total RNA was extracted with TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions. Quantitative real-time RT-PCR
analysis was performed by LightCycler (Roche) and SYBR RT-PCR
kit (Takara, Dalian, China). The primers used for mHRPT, IFN-4a,
and IFN-b analysis were described previously (Takaoka et al.,
2005; Karaghiosoff et al., 2003). TNF-a and IL-6 primers were ob-
tained from Biosource. Data were normalized by the level of HPRT
expression in each sample.
Immunoprecipitation and Immunoblot
Cells were lysed with M-PER Protein Extraction Reagent (Pierce,
Rockford, IL) supplemented with protease inhibitor cocktail. Protein
concentrations of the extracts were measured with BCA assay
(Pierce). 50 mg of protein was either used for immunoprecipitation,
or loaded and subjected to SDS-PAGE, transferred onto nitrocellu-
lose membranes, and then blotted as described previously (An
et al., 2005).
Assay of Luciferase Reporter Gene Expression
RAW264.7 macrophages, HEK 293 cells, or mouse embryonic fibro-
blasts were cotransfected with the mixture of indicated luciferase re-
porter plasmid, pRL-TK-Renilla-luciferase plasmid, and indicated
amounts of SHP-2, TRIF, or TBK1 construct. Total amounts of plas-
mid DNA were equalized via empty control vector. After 24 hr, the
cells were left untreated or treated with TLR agonists. Luciferase
activities were measured with Dual-Luciferase Reporter Assay
System (Promega) according to the manufacturer’s instructions.
Data are normalized for transfection efficiency by dividing Firefly
luciferase activity with that of Renilla luciferase.Pull-Down Assay
Purified recombinant active TBK1 was incubated with GST-tagged
SHP-2 (amino acid 330–545) at 4C for 30 min and incubated with
glutathione-agarose at 4C for another 2 hr in IP buffer containing
NP40. After washing three times, the pellet of agarose was analyzed
by immunoblot.
TBK1 Kinase Activity Assay
TBK1 kinase activity was assayed with Chemiluminescent MBP
Assay Kit (Upstate Biotechnology). 100 mg of recombinant GST or
GST-SHP-2 (amino acid 330–545) in assay buffer was added to
MBP-coated well containing Magnesium/ATP buffer. Then, 100 ng
of recombinant TBK1 in assay buffer was added to appropriate
wells. After incubation for 20 min, the wells were washed with wash-
ing buffer and blocked with blocking buffer. HRP-conjugated anti-
phospho-MBP (phosphorylated threonine) in blocking buffer was
added to the wells. After washing with PBS and washing buffer,
LumiGLO Chemiluminescent substrate was added. Luminescent in-
tensity was assayed with luminometer according to manufacturer’s
instructions.
Statistical Analysis
Statistical significance was determined by Student’s t test, with
a value of p < 0.05 considered to be statistically significant.
Supplemental Data
Eight Supplemental Figures and can be found with this article online
at http://www.immunity.com/cgi/content/full/25/6/919/DC1/.
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